# Nuvectis Pharma, Inc.  (NVCT)

Nuvectis Pharma files for $150 million mixed securities shelf offering, signaling potential for future growth and investment. Anticipation builds around NXP900 drug data expected in Q2, with some analysts reiterating a 'Buy' rating and a $17.00 price target.

### About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on developing and deploying advanced technological solutions.  
Nuvectis Pharma, Inc.  uses the ticker $NVCT for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights
- Nuvectis Pharma, Inc.  (NVCT) mentions hit [---] which is 536% higher than it's daily average.
- Nuvectis Pharma, Inc.  (NVCT) creators hit [--] which is 310% higher than it's daily average.
- Nuvectis Pharma, Inc.  (NVCT) social dominance hit [------] which is 360% higher than it's daily average.
- Nuvectis Pharma, Inc.  (NVCT) trading volume is up 1094.76% from the previous month.
- Nuvectis Pharma, Inc.  (NVCT) social dominance is up 2371.43% from the previous [--] months.
- Nuvectis Pharma, Inc.  (NVCT) Galaxy Score™ is up 50% from the previous [--] months.
- Nuvectis Pharma, Inc.  (NVCT) engagements is up 279.65% from the previous week.
- Nuvectis Pharma, Inc.  (NVCT) posts created is up 66.67% from the previous week.
- Nuvectis Pharma, Inc.  Price hit a 52-Week high of $9.50 for the hour
- Nuvectis Pharma, Inc.  Price hit an all time of $9.50 for the hour

### Price: $8.80
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$nvct/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$nvct/time-series/close.tsv)  
The current upward price action, reaching a 52-week high, is likely driven by significant surges in social media engagement and positive sentiment, particularly around the anticipated NXP900 drug data and a recent mixed securities shelf offering.  

24-Hour: -0.45%
7-Day: -1.46%
30-Day: 3.3%

1-Year High: $9 on 2026-02-09  
1-Year Low: $5.70 on 2025-11-05  
  
  
### AltRank: [-----]
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$nvct/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$nvct/time-series/alt_rank.tsv)  
Nuvectis Pharma, Inc.  (NVCT) is currently AltRank #1,409 based on combined combined social and market metrics
Daily Average: [-----]  
[--] Week: [-----] [----]  
1-Year High: [-----] on 2026-02-11  
1-Year Low: [---] on 2026-01-24  
  
  
### Galaxy Score: [-----]
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$nvct/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$nvct/time-series/galaxy_score.tsv)  
Current Value: [-----]  
Daily Average: [--]  
[--] Week: [--] +5  
[--] Month: [--] +3  
[--] Months: [--] [---]  
[--] Year: [--] [---]  
1-Year High: [--] on 2026-01-24  
1-Year Low: [--] on 2025-04-25  
  
  
### Engagements: [-----] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$nvct/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$nvct/time-series/interactions.tsv)  
Current Value: [-----]  
Daily Average: [-----]  
[--] Week: [------] +280%  
[--] Month: [------] +53%  
[--] Months: [-------] -38%  
[--] Year: [-------] -16%  
1-Year High: [------] on 2025-06-20  
1-Year Low: [--] on 2025-08-24  

Engagements by network (24h):
Reddit: [--]
News: [--]
YouTube: [--]
X: [-----]

  
  
### Mentions: [---] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$nvct/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$nvct/time-series/posts_active.tsv)  
Current Value: [---]  
Daily Average: [--]  
[--] Week: [---] -11%  
1-Year High: [---] on 2025-06-28  
1-Year Low: [--] on 2025-05-25  

Mentions by network (24h):
Reddit: [--]
News: [--]
YouTube: [--]
X: [---]

  
  
### Creators: [--] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$nvct/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$nvct/time-series/contributors_active.tsv)  
[--] unique social accounts have posts mentioning Nuvectis Pharma, Inc.  (NVCT) in the last [--] hours which is up 86% from [--] in the previous [--] hours
Daily Average: [--]  
[--] Week: [--] -18%  
1-Year High: [---] on 2025-06-28  
1-Year Low: [--] on 2025-06-05  

The most influential creators that mention Nuvectis Pharma, Inc.  in the last [--] hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@semodough](/creator/twitter/semodough)             | [--]    | [------]    | [--]     | [---]         |
| [@kjerath](/creator/twitter/kjerath)                 | [--]    | [---]       | [--]     | [---]         |
| [@JD4for4](/creator/twitter/JD4for4)                 | [--]    | [-----]     | [--]     | [---]         |
| [@tradingsssss](/creator/twitter/tradingsssss)       | [--]    | [-----]     | [--]    | [---]         |
| [@LabbRadar](/creator/twitter/LabbRadar)             | [--]    | [-----]     | [--]     | [---]         |
| [@DalvinVarnado](/creator/twitter/DalvinVarnado)     | [--]    | [------]    | [--]     | [---]         |
| [@Omnitrader69](/creator/twitter/Omnitrader69)       | [--]    | [-----]     | [--]     | [--]          |
| [@Ella55005](/creator/twitter/Ella55005)             | [--]    | [--]         | [--]     | [--]          |
| [@Stock_Marketr13](/creator/twitter/Stock_Marketr13) | [--]    | [---]       | [--]    | [--]          |
| [@BillMiller32](/creator/twitter/BillMiller32)       | [--]   | [-----]     | [--]     | [--]          |

[View More](/list/creators/$nvct/100)
  
  
### Sentiment: 53%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$nvct/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$nvct/time-series/sentiment.tsv)  
Current Value: 53%  
Daily Average: 72%  
[--] Week: 33% -54%  
[--] Month: 53% +38%  
[--] Months: 53% -47%  
[--] Year: 53% -47%  
1-Year High: 100% on 2025-02-15  
1-Year Low: 4% on 2026-01-19  

Most Supportive Themes:
- Technological Innovation: (40%) Posts highlighting new product developments and research breakthroughs.
- Industry Leadership: (30%) Content showcasing Nova Cadrus Technologies' influence and expertise in the tech sector.
  
Most Critical Themes:
- Market Competition: (25%) Discussions and analyses comparing Nova Cadrus Technologies with its competitors.
- Regulatory Landscape: (5%) Information and opinions regarding the impact of new regulations on the company's operations.
  
  
  
### Social Dominance: 0.011%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$nvct/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/$nvct/time-series/social_dominance.tsv)  
Current Value: 0.011%  
Daily Average: 0.00376%  
[--] Week: 0.0062% +0.0054%  
[--] Month: 0.017% +0.016%  
[--] Months: 0.017% +0.017%  
[--] Year: 0.017% +0.012%  
1-Year High: 0.03% on 2025-06-29  
1-Year Low: 0.0003% on 2025-08-25  
  
  
### Market Dominance: 0.0002628068335638365%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$nvct/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/$nvct/time-series/market_dominance.tsv)  
Current Value: 0.0002628068335638365%  
Daily Average: 0%  
1-Year High: 0.011% on 2026-02-06  
1-Year Low: 0.00026% on 2026-02-14  
  
  
### Market Cap: $232,067,310
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$nvct/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$nvct/time-series/market_cap.tsv)  
Current Value: $232,067,310  
Daily Average: $222,001,141  
[--] Week: $232,332,227 +1.90%  
[--] Month: $232,067,310 +6.20%  
1-Year High: $239,484,986 on 2026-02-09  
1-Year Low: $207,736,807 on 2026-01-20  

### Top Nuvectis Pharma, Inc.  Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"$NVCT: Nuvectis Pharma files for $150 mln mixed securities shelf offering https://www.briefing.com/in-depth-analysis/Content/ArticleArticleId=IN20260213160622NVCT&utm_campaign=inplay&utm_medium=social&utm_source=twitter&utm_content=view_page https://www.briefing.com/in-depth-analysis/Content/ArticleArticleId=IN20260213160622NVCT&utm_campaign=inplay&utm_medium=social&utm_source=twitter&utm_content=view_page"  
[X Link](https://x.com/Briefingcom/status/2022447510288240775) [@Briefingcom](/creator/x/Briefingcom) 2026-02-13T23:07Z 34.5K followers, [---] engagements


"$NVCT is a coiled spring ready to move from its [--] year downturn. It may take time or it may start now. Depends on when the chart breaks. Data expected in Q2. If good these prices will never be seen again"  
[X Link](https://x.com/kjerath/status/2022020806000394250) [@kjerath](/creator/x/kjerath) 2026-02-12T18:51Z [---] followers, [---] engagements


"Long $NVCT. Enrolment for NXP900 ph 1b EGFR arm is progressing in a positive direction $NVCT Maxim $NVCT- $8.78- Buy-$17.00PT): 4Q25 Review & Outlook: NXP900 Phase 1b EGFR Arm Enrolling ALK Arm Pending Enrollment Reiterate Buy on NSCLC Opportunity $NVCT Maxim $NVCT- $8.78- Buy-$17.00PT): 4Q25 Review & Outlook: NXP900 Phase 1b EGFR Arm Enrolling ALK Arm Pending Enrollment Reiterate Buy on NSCLC Opportunity"  
[X Link](https://x.com/LabbRadar/status/2021956870832025783) [@LabbRadar](/creator/x/LabbRadar) 2026-02-12T14:37Z [----] followers, [---] engagements


"$NVCT Maxim $NVCT- $8.78- Buy-$17.00PT): 4Q25 Review & Outlook: NXP900 Phase 1b EGFR Arm Enrolling ALK Arm Pending Enrollment Reiterate Buy on NSCLC Opportunity"  
[X Link](https://x.com/semodough/status/2021934105102045401) [@semodough](/creator/x/semodough) 2026-02-12T13:07Z 42.5K followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing